Universität Wien

301908 VO Development of novel cancer immunotherapies (2024S)

from target identification through target validation to clinical trials

3.00 ECTS (2.00 SWS), SPL 30 - Biologie

Registration/Deregistration

Note: The time of your registration within the registration period has no effect on the allocation of places (no first come, first served).

Details

Language: English

Examination dates

Lecturers

Classes (iCal) - next class is marked with N

-digitale Lehre-
blocked., starts in april
more information follows

  • Tuesday 09.04. 15:00 - 17:00 STB/Hörsaal A Campus Vienna Biocenter 5, 1030 Wien
  • Tuesday 16.04. 15:00 - 16:55 BZB/Seminarraum 1/2, 6.Ebene 6.501/6.504, Dr.-Bohr-Gasse 9, 1030 Wien
  • Tuesday 23.04. 15:00 - 17:00 BZB/Seminarraum 1/2, 6.Ebene 6.501/6.504, Dr.-Bohr-Gasse 9, 1030 Wien
  • Tuesday 30.04. 15:00 - 16:55 BZB/Seminarraum 1/2, 6.Ebene 6.501/6.504, Dr.-Bohr-Gasse 9, 1030 Wien
  • Tuesday 07.05. 15:00 - 16:55 BZB/Seminarraum 1/2, 6.Ebene 6.501/6.504, Dr.-Bohr-Gasse 9, 1030 Wien
  • Tuesday 14.05. 15:00 - 16:55 BZB/Seminarraum 1/2, 6.Ebene 6.501/6.504, Dr.-Bohr-Gasse 9, 1030 Wien
  • Friday 17.05. 09:00 - 19:00 BZB/Seminarraum, 3.Ebene 3.202/3.402, Dr.-Bohr-Gasse 9, 1030 Wien

Information

Aims, contents and method of the course

The aim of the lecture is to transport the basic molecular, cellular and technological knowledge that is important for our understanding of current resistance mechanisms occurring in current immunotherapies. In Part II I will discuss state of the art methods which are currently employed to enhance our understanding of these mechanisms at play.

Assessment and permitted materials

Written exam, alternative: presentation

Minimum requirements and assessment criteria

Understanding of the basic mechanisms of resistance development and of newest technologies

Examination topics

Reading list


Association in the course directory

MMEI II-3.2, MMEI III, WZB, MMB IV., MNEU V, MMB IV-2, MMB W-2, MGE III-1, MES5

Last modified: Th 19.09.2024 14:06